Check it down what types of cancer can be prevented with the vaccine against human papilloma virus (HPV)

 

High-risk HPV types cause approximately 5% of all cancers worldwide. In the United States, high-risk HPV types cause approximately 3% of all cancer cases among women and 2% of all cancer cases among men.

High-risk HPVs cause several types of cancer.

Cervical cancer: Virtually all cases of cervical cancer are caused by HPV, and just two HPV types, 16 and 18, are responsible for about 70% of all cases.

Anal cancer: About 95% of anal cancers are caused by HPV. Most of these are caused by HPV type 16.

Oropharyngeal cancers (cancers of the middle part of the throat, including the soft palate, the base of the tongue, and the tonsils): About 70% of oropharyngeal cancers are caused by HPV. In the United States, more than half of cancers diagnosed in the oropharynx are linked to HPV type 16.

Rarer cancers: HPV causes about 65% of vaginal cancers, 50% of vulvar cancers, and 35% of penile cancers. Most of these are caused by HPV type 16.

DOCTOR MENDOZA CANCER NEWS : Chronic stress may promoteresistance to lung canc...

DOCTOR MENDOZA CANCER NEWS :
Chronic stress may promoteresistance to lung canc...: Chronic stress may promote resistance to lung cancer therapy Elevated levels of chronic stress hormones, such as those produced by ps...

DOCTOR MENDOZA CANCER NEWS : Symptomsof ovarian cancerIf you regularly experi...

DOCTOR MENDOZA CANCER NEWS :
Symptomsof ovarian cancer
If you regularly experi...: Symptoms of ovarian cancer If you regularly experience any of these symptoms, which are not normal for you, it is important that you ...

The prevention is worth than a cure. Avoid the cancer risks!

 

New hope: Nivolumab Approved for metastatic and unresectable Liver Cancer.

Nivolumab (Opdivo, Bristol-Myers Squibb) has been approved by the US Food and Drug Administration (FDA) for use in the treatment of hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib (Nexavar, Bayer).
The immunotherapy is already approved for use in many different cancer types, including melanoma, lung and kidney cancer, and Hodgkin's lymphoma.
This latest indication is an accelerated approval based on tumor response rates and durability of response, as seen in the CheckMate-040 trial, a single-arm phase1/2 trial.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials, the company noted.
The trial was conducted in 154 patients with HCC who had progressed on, or were intolerant of, sorafenib.  All patients received nivolumab 3 mg/kg administered intravenously every 2 weeks.

The overall response rate was 14.3% (22 of 154 patients), with 3 patients (1.9%) showing a complete response and 19 patients (12.3%) a partial response. The duration of the responses ranged from 3.2 to 38.2+ months; 91% of those patients had responses of 6 months or longer and 55% had responses of 12 months or longer, the manufacturer noted in a press release.